Eansor Norman David

Average Profitability
<0.0001%
Insider Buys Quantity
1
Insider Buys Sum
$249,987.50
Insider Sells Quantity
10
Insider Sells Sum
$47.29M

Insider Activity of Eansor Norman David

The largest purchase of all time was on 2021-03-16 and amounted to 14285 shares of Marker Therapeutics, Inc. for $249,988.

The largest sale of all time was on 2021-11-12 and amounted to 27159 shares of Bio-Techne Corporation for $13.69M.

Biography of Eansor Norman David

No biography is available at this moment.

2021-11-12SaleBio-Techne Corporation
TECH
President-Protein Sciences
27,159
0.069%
$504.00$13.69M-25.52%
2021-08-31SaleBio-Techne Corporation
TECH
President-Protein Sciences
1,538
0.004%
$503.07$773,728-16.73%
2021-03-16PurchaseMarker Therapeutics, Inc.
MRKR
director
14,285
0.238%
$17.50$249,988-4.3%
2021-02-05SaleBio-Techne Corporation
TECH
President-Protein Sciences
32,933
0.0848%
$380.68$12.54M+19.05%
2020-05-29SaleBio-Techne Corporation
TECH
President-Protein Sciences
15,818
0.041%
$262.00$4.14M+14.9%
2020-05-28SaleBio-Techne Corporation
TECH
President-Protein Sciences
6,896
0.0129%
$184.34$1.27M+17.66%
2020-05-22SaleBio-Techne Corporation
TECH
President-Protein Sciences
25,200
0.0663%
$267.93$6.75M+13.93%
2020-05-21SaleBio-Techne Corporation
TECH
President-Protein Sciences
22,074
0.0579%
$267.49$5.9M+13.79%
2020-03-04SaleBio-Techne Corporation
TECH
President-Protein Sciences
2,774
0.0073%
$198.68$551,138+34.5%
2019-06-12SaleBio-Techne Corporation
TECH
SVP - Novus Biologicals
6,234
0.0165%
$215.00$1.34M-3.29%
2018-05-04SaleBio-Techne Corporation
TECH
SVP - Novus Biologicals
2,272
0.006%
$145.19$329,864+17.74%
Total: 11
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.